NEW YORK (Reuters) – Novartis AG said on Wednesday it will pay $245 million to resolve civil litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of the Exforge blood pressure treatment.
The settlements with so-called direct purchasers, indirect purchasers and retailers require approval by a federal judge in Manhattan, and will resolve all outstanding claims against the company over the matter, Novartis said.
(Reporting by Jonathan Stempel in New York; Editing by Muralikumar Anantharaman)
